Compositions and methods for the treatment of chronic lymphocytic leukemia

Abstract

Methods for treating patients with CLL with pharmaceutical agents are disclosed. The methods of the present invention can be used in patients that have not responded to standard treatment. In addition, the methods can be used to augment the impact of standard chemotherapy.

I claim,  
     
         1 . A method, comprising: 
 a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and ii) a formulation comprising an inhibitor that specifically inhbits Type 4 cyclic adenosine monophosphate phosphodiesterases; and    b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.    
     
     
         2 . The method of  claim 1 , wherein said administering is enteral administration.  
     
     
         3 . The method of  claim 2 , wherein said enteral administration is oral administration.  
     
     
         4 . The method of  claim 1 , wherein said administering is parenteral administration.  
     
     
         5 . The method of  claim 1 , wherein said patient is a naive patient.  
     
     
         6 . The method of  claim 1 , wherein said patient is immunocompromised.  
     
     
         7 . The method of  claim 1 , wherein said patient is unresponsive to chemotherapy with alkylating agents.  
     
     
         8 . A method, comprising: 
 a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and ii) a formulation comprising rolipram; and    b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.    
     
     
         9 . The method of  claim 8 , wherein said administering is enteral administration.  
     
     
         10 . The method of  claim 9 , wherein said enteral administration is oral administration.  
     
     
         11 . The method of  claim 8 , wherein said administering is parenteral administration.  
     
     
         12 . The method of  claim 8 , wherein said patient is a naive patient.  
     
     
         13 . The method of  claim 8 , wherein said patient is immunocompromised.  
     
     
         14 . The method of  claim 8 , wherein said patient is unresponsive to chemotherapy with alkylating agents.